Search

Displaying results 9201 - 9210 of 10000 in total
  1. Drug

    NAV 1800

    go.drugbank.com/drugs/DB05437
    Experimental

    RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal cancer.

  2. Drug

    IRX-2

    go.drugbank.com/drugs/DB05643
    Investigational

    It is being investigated to promote or enhance an anti-cancer immune response.

  3. Drug

    FavId

    go.drugbank.com/drugs/DB05249
    Investigational

    FavId, is an active immunotherapy that is based upon unique genetic information extracted from a patient's tumor.

  4. Drug

    ATL-104

    go.drugbank.com/drugs/DB05670
    Investigational

    In animal models, ATL-104 aids regeneration of the gastrointestinal tract after treatment with chemotherapeutic agents.

  5. Drug

    Fluindione

    go.drugbank.com/drugs/DB13136
    ApprovedWithdrawn

    Fluindione is under investigation for the treatment of Venous Thrombosis, Pulmonary Embolism, Permanent Atrial Fibrillation, and Anticoagulating Treatment on a Duration at Least 12-month-old Superior.

  6. Drug

    Talbutal

    go.drugbank.com/drugs/DB00306
    ApprovedIllicit

    Talbutal is a schedule III drug in the U.S.

  7. Drug

    Dextrorphan

    go.drugbank.com/drugs/DB14682
    Experimental

    Synonyms: d-3-hydroxy-N-methylmorphinan, Levorphanol D-formCategories: Compounds used in a research, industrial, or household setting
  8. Drug

    Cepharanthine

    go.drugbank.com/drugs/DB16824
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Ferrous succinate

    go.drugbank.com/drugs/DB14489
    ApprovedInvestigational

  10. Drug

    EpiVacCorona

    go.drugbank.com/drugs/DB16439
    Investigational

    EpiVacCorona Vaccine, developed by the Vektor State Research Center of Virology and Biotechnology in Russia, is based on peptide-antigens that facilitate immunity to the SARS-CoV-2 virus[L30608]. … It is currently being tested in Phase I/II clinical trials for safety and immunogenicity (NCT04527575)[L30608, L30613].